Login to Your Account



Regulus retreads jaundice scare, triggering clinical hold

By Michael Fitzhugh
Staff Writer

Tuesday, June 28, 2016

A serious new case of jaundice that developed during a Regulus Therapeutics Inc. study of RG-101 for the treatment of chronic HCV triggered the FDA to issue a verbal clinical hold on the program, sending company shares (NASDAQ:RGLS) down 49.3 percent to $2.54 on Tuesday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription